Integrating synthetic chemistry with synthetic biology allows rapid access to xenobiotic compounds which may provide improved therapeutic activity. By supplementing an Escherichia coli strain expressing the violacein biosynthesis pathway with eight tryptophan substrate analogues or tryptophan halogenase RebH in vivo, 68 new-to-nature analogues of violacein were generated. Furthermore, 20 new derivatives were generated from brominated analogues via Suzuki-Miyaura cross-coupling reaction directly using the crude extract without prior purification. Herein, we demonstrate a flexible and rapid approach to access diverse chemical space that can be applied to a wide range of natural product scaffolds.
Main
Total synthesis of natural products and their analogues has often been challenging and costly due to their structural complexities 1 . However, greater chemical space may be accessed through utilisation of synthetic chemistry methodologies and reagents compared to enzymecatalysed biosynthesis alone. Combining biosynthesis with chemical synthesis represents a powerful approach for rapidly generating new analogues of complex natural products and libraries of chemical derivatives suitable for screening and structure-activity relationship (SAR) assays 2,3 , leading to discovery of new and more potent compounds. The generation of such analogues can enable improvement in bioactivity and bioavailability, as illustrated for example by analogues of the 'last-resort' antibiotic vancomycin, with >200-fold improvement of potency compared to vancomycin in resistant Enterococci strains 4 . In another study, the addition of a sterically unhindered primary amine group to a Gram-positive antibiotic deoxynybomycin expanded its antimicrobial activity to multi-drug-resistant Gram-negative pathogenic strains 5 .
As a proof-of-concept, we have focused on the violacein biosynthesis pathway. Violacein (1),a violet pigment first isolated from the bacterium Chromobacterium violaceum, is part of the bisindole biosynthetic family that utilises L-tryptophan as the starting substrate. The violacein pathway is encoded within a conserved operon of five genes (vioABCDE), whose geneproducts catalyse a 14-electron oxidative biosynthesis pathway 6 (Figure S1). The bisindole biosynthetic pathways have attracted considerable interest because of their therapeutic potential for medical applications, including antimicrobial, antiviral, trypanocidal and antitumorigenic properties 7 . The violacein biosynthetic pathway also produces deoxyviolacein (2) as a by-product, and the coloured properties of violacein and deoxyviolacein make them interesting targets for natural product pathway engineering, such as promoter library screening 8 , CRISPR-based multiplex transcriptional regulation 9 or diverting pathway flux via RBS engineering 10 .
A study on oxyviolacein, a hydroxylated analogue of violacein generated by feeding exogenous 5-hydroxy-L-tryptophan 11 , showed bioactivity against a collection of pathogenic bacteria and fungi strains 12 suggesting that violacein analogues may be a good starting point for developing more potent antibiotics. Although total chemical synthesis of violacein 13, 14 and some substituted analogues 15, 16 have been reported, pathway manipulation could represent a more flexible and rapid approach for generating violacein analogues. Other examples of using altered biosynthetic pathways for analogue generation, include using various enzyme homologues from bisindole pathways 17, 18 , interconversion of the biosynthetically related novobiocin and clorobiocin aminocoumarin antibiotics 19 , and introduction of the halogenase from hormaomycin pathway to generate clorobiocin analogues 20 . In this study, we have applied such approaches to generate 86 new violacein or deoxyviolacein analogues via a combination of enzymatic halogenation of the starting substrate tryptophan, feeding different substrate analogues, and further derivatization using Suzuki-Miyaura cross-coupling directly in crude extracts (Figure 1) . Table S1) . Surprisingly, the structures show that the tryptophan analogues bind the VioA active site in different conformations, presumably to accommodate the substituted fluorine or methyl group at C4 to C7 positions (Figure 2b) . However, the interatomic distances between respective Cα atom or amine nitrogen atom and N5 of FAD cofactor is conserved for all the analogues (between 3.93 Å to 4.69 Å for Cα atom, 3.62 Å to 5.63 Å for amine nitrogen) and is similar to the TRP-bound structure (3.93 Å for Cα atom and 5.07 Å for amine nitrogen). This showed that all the analogues can bind VioA in a catalytically active, but slightly different conformation (Table S2) Having determined that VioA accepts various tryptophan analogues, we next investigated the potential for derivatizing violacein using a substrate feeding approach, using commercially available tryptophan analogues as starting precursors. This included 4-fluoro-, 5-fluoro-, 6fluoro-, 5-chloro-, 5-hydroxyl-, 6-methyl-and 7-methyl-substituted tryptophan analogues. By adding the tryptophan analogues to cultures of E. coli cells that were expressing a synthetic violacein biosynthesis pathway vioABCDE (Figure 2c) , a total of 62 new compounds were observed including structural isomers due to the asymmetry of the violacein core scaffold, demonstrating promiscuity of violacein biosynthesis enzymes (chemical structures in Table   S3 ). The percentage compositions of the various violacein and deoxyviolacein analogues were calculated based on the extracted total ion chromatogram (TIC) peak area obtained from LC-MS/MS analyses (Table S4, Figure 2d ). We then assayed the growth inhibitory activity of the crude violacein extracts containing the various analogues and a control containing only the underivatized scaffolds against Bacillus subtilis cultures as a Gram-positive model organism. Using crude extracts of violacein analogues we observed few changes in growth inhibition compared to the extracts containing unmodified crude violacein (Figures S9) .
Interestingly, the 6MeT extract has about 4-fold higher IC50 compared to the 7MeT extract, where the only difference between these two samples is the position of methyl group attached to the indole ring, suggesting that the C6 substitution might be important for activity. In addition, cell extracts containing only deoxyviolacein did not show any significant inhibition towards B.
subtilis, suggesting that the 5-hydroxyl group of violacein confers the antimicrobial activity, in agreement with previous studies 12, 21, 22 .
Due to the promiscuity of violacein biosynthesis pathway enzymes, we rationalized that a combination of enzymes from closely related bisindole biosynthesis pathways (Figure S2) could generate compatible tryptophan analogues leading to other interesting new-to-nature analogues of violacein that might be otherwise difficult to synthesise. Rebeccamycin is a closely related bisindole where the biosynthetic pathway contains several genes including rebO and rebD which are homologous to vioA and vioB respectively. In addition, the pathway also consists of a tryptophan 7-halogenase RebH and its associated flavin reductase RebF that are responsible for generating 7-chloro-L-tryptophan from L-tryptophan via a chloraminelysine intermediate 23, 24 . As a proof-of-principle, we combined the rebeccamycin (Reb) and violacein (Vio) biosynthetic operons using the Golden Gate cloning kit EcoFlex 25 in order to generate C7-chlorinated violacein analogues which we were able to successfully produce in E. coli cells (Figure 2e) identified via LC-MS/MS (Table S4 ). We found that although the RebOD+VioCDE strain (lacking RebFH) did not produce any chlorinated analogues of violacein, it was able to functionally substitute VioAB to produce violacein and deoxyviolacein 6 .
Next, by comparing RebFH+VioABCDE and RebFHOD+VioCDE (where RebOD replaced VioAB) strains, we observed that RebOD increased the proportion of chlorinated analogues from 6% to 33% when compared with VioAB (Figure 2f) . This was likely due to the fact that RebO has kcat/Km value 57-times higher for 7-Cl-L-tryptophan than that of L-tryptophan 26 
, thus
RebO and RebD preferentially accept the 7-chloro analogue of L-tryptophan and IPA imine respectively, producing the 7-chlorinated intermediate for downstream enzymes in the violacein biosynthesis pathway. By replacing the weak promoter J23114 for RebF and RebH with a medium strength promoter J23108, we also observed a total analogue increase of nearly 30% (Figure 2g) . This shows that it is possible to fine tune the proportion of chlorinated analogue by changing the promoter strength of pathway enzymes, and optimization of fermentation protocols such as length of incubation, temperature, media conditions might further increase both proportion and the total amount of chlorinated analogues 8 .
Further derivatisation, through chemical cross-coupling, of new-to-nature, halogenated natural product analogues generated by a synthetic biological strain, was first demonstrated with pacidamycins 27 . We applied a similar strategy by first feeding 5-bromo-DL-tryptophan to E. coli cells expressing VioABCDE to generate 5'-bromo-violacein and 5'-bromo-deoxyviolacein which were detected by LC-MS/MS (Table S4 ). We then proceeded to screen a series of conditions that might facilitate Suzuki-Miyaura cross-coupling. However, due to low titres of 5'-bromo-violacein and 5'-bromo-deoxyviolacein available in the crude extract, isolation of products for further characterisation and bioassays of the cross-coupling product proved difficult (see SI Extended Data). We thus focused on systemically identifying conditions that would allow direct cross-coupling in crude extracts which identified optimal conditions for derivatization (Tables S6-S8 ). The corresponding cross-coupling products 5'-(p-tolyl)violacein and 5'-(p-tolyl)-deoxyviolacein were detected in the cross-coupling mixture by LC-MS/MS (Figure 3a, Table S5 ). Having identified the optimised conditions for cross-coupling at low concentrations, we performed cross-coupling reaction with a selection of 15 aryl boronic acids chosen to sample a wide range of steric and electronic variations, which gave a total of 20 new cross-coupled analogues of violacein and deoxyviolacein (Figure 3b) . We observed that while boronic acids with electron-donating groups (e.g. p-methoxyphenylboronic acid) gave better yield and MS/MS data were obtained, for those with electron-withdrawing groups (e.g. p-formylphenylboronic acid), only MS data were obtained due to lower conversion and more difficult electrospray ionisation of corresponding violacein analogues (Table S5) .
Pleasingly, even boronic acid pinacol esters were successfully converted into the corresponding violacein product (e.g. p-cyanophenylboronic acid pinacol ester). In summary, the optimised conditions showed that a variety of cross-coupling analogues could be synthesised without the need for purification prior to cross-coupling, allowing for rapid access to potential cross-coupling products.
In conclusion, inspection of the biosynthetic assembly of the antibiotic violacein and crystal structure analyses of the first enzyme VioA, suggested that various tryptophan substrate analogues could be enzymatically processed. We utilized this finding and designed experiments in which we have powerfully combined biosynthesis and synthesis to enable rapid access to 68 new violacein and deoxyviolacein analogues only one of which has been described previously (oxyviolacein 11, 12 ). Furthermore, we have extended this portfolio of compounds further via Suzuki-Miyaura cross-coupling reactions on the new-to-nature natural products that have been generated, accessing an additional series of 20 violacein or deoxyviolacein coupling products. The ability to carry out these synthetic diversifications selectively on the halometabolites as components of a crude cell extract is exciting, opening the way for applying this approach to building of more diverse libraries of analogues. Although an initial growth inhibition screen of B. subtilis using crude extracts showed little change in activity compared with extracts containing violacein and deoxyviolacein, this is likely to reflect the increased lipophilicity (LogP) of the halogenated or methylated compounds, and could be potentially overcome using cross-coupling through the exploration of a series of more polar partners. Finally, the combination of synthetic chemistry with synthetic biology, provides a more sustainable approach with the potential for application towards generating analogues of natural products in order to access greater chemical diversity rapidly and predictably. (1), deoxyviolacein (2), violacein analogues and deoxyviolacein analogues based on extracted TIC peak area in crude extracts of E. coli cells fed with various tryptophan substrates. (e) Schematic of the hybrid rebeccamycin-violacein pathway enzymes that lead to 7-chloro analogues of violacein (9) and deoxyviolacein (10a, 10b, 10c ). (f) Percentage compositions of 7-chloro analogues of violacein and deoxyviolacein extracted from different E. coli strains expressing three pathway combinations (P1, P2, P3) based on extracted TIC peak area. Data shows mean with n=2. (g) Percentage compositions of 7-chloro analogues of violacein and deoxyviolacein extracted from E. coli expressing RebFHOD+VioCDE with different combinations of medium (J23108) and weak (J23114) promoters controlling the expression of RebF, RebH and VioD based on extracted TIC peak area. Data shows mean with n=3. Relative analogues peak area show mean with SD, n=3. Table S5 ). ND, not detected.
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